NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
about
Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCVShort-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1.Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients.The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.Grazoprevir/elbasvir treatment for the relapse of HCV genotype 1b infection after ledipasvir/sofosbuvir: A case reportHepatitis C resistance to NS5A inhibitors: Is it going to be a problem?2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
P2860
Q30843427-37F9A90C-02AD-400F-B1A7-1A723FC8476FQ38724160-2FEF5ED0-1EE9-4508-80E3-8C054E3838ADQ40228687-E4DDCB1B-EE17-49C1-94D0-1E8B6024F6E0Q45326298-1A803101-AF54-4BF0-957A-C9863E11CCA6Q47560943-ED25EEA4-311E-4113-8EE5-01151625B741Q47572297-CD9683DB-15FA-40C3-AD5A-F2BFBFCE68ACQ47642315-870C54B9-3920-4CE0-864C-3504519679B9Q47657221-23F4EAEC-3018-4C75-AA54-CB6E399BF0F0Q49238531-47876F1E-E02B-48A2-B7AF-4C3FA5E1FD2FQ55212538-2DE9A5F8-B0C6-4B14-A208-BA3F0F6D9905Q56524474-0CDB5371-5DEE-4B46-AC5B-4456C56E4B7BQ57491238-75C900D6-0FFA-4119-956A-9AC68BD9A953Q58788714-9A8FF3F4-54DF-49F0-A0DB-AAE4B2908E4E
P2860
NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
NS5A resistance-associated var ...... infected with HCV genotype 1b.
@en
NS5A resistance-associated var ...... infected with HCV genotype 1b.
@nl
type
label
NS5A resistance-associated var ...... infected with HCV genotype 1b.
@en
NS5A resistance-associated var ...... infected with HCV genotype 1b.
@nl
prefLabel
NS5A resistance-associated var ...... infected with HCV genotype 1b.
@en
NS5A resistance-associated var ...... infected with HCV genotype 1b.
@nl
P2093
P2860
P1476
NS5A resistance-associated var ...... infected with HCV genotype 1b.
@en
P2093
Akira Kawano
Eiichi Ogawa
Eiji Kajiwara
Hideyuki Nomura
Jun Hayashi
Kazufumi Dohmen
Kazuhiro Takahashi
Koichi Azuma
Kyushu University Liver Disease Study (KULDS) Group
Makoto Nakamuta
P2860
P304
P356
10.1007/S00535-016-1290-1
P577
2016-12-02T00:00:00Z